These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 421716)

  • 1. Comparison between the effects of Micrococcus lysodeikticus, bacterial cell wall and related polysaccharides in the nonspecific tumour immunotherapy of Ehrlich ascites tumour growth.
    Verloes R; Atassi G; Dumont P; Kanarek L
    Eur J Cancer (1965); 1979 Jan; 15(1):53-61. PubMed ID: 421716
    [No Abstract]   [Full Text] [Related]  

  • 2. Non-specific tumour immunotherapy by Micrococcus lysodeikticus and related polysaccharides [proceedings].
    Verloes R; Kanarek L
    Arch Int Physiol Biochim; 1977 Dec; 85(5):1028-9. PubMed ID: 79358
    [No Abstract]   [Full Text] [Related]  

  • 3. Superiority of Micrococcus lysodeikticus to BCG in chemo-immunotherapy of advanced L1210 leukaemia.
    Verloes R; Atassi G
    Eur J Cancer Clin Oncol; 1981 Aug; 17(8):849-56. PubMed ID: 6799298
    [No Abstract]   [Full Text] [Related]  

  • 4. Tumour immunoprophylaxis exerted by the antimicrococcus immunity. II. Influence on the proliferation of murine plasmacytoma (MOPC 176) and Ehrlich carcinoma cells.
    Verloes R; Atassi G; Dumont P; Kanarek L
    Eur J Cancer (1965); 1978 Dec; 14(12):1321-9. PubMed ID: 738337
    [No Abstract]   [Full Text] [Related]  

  • 5. Successful immunotherapy with micrococcus, BCG or related polysaccharides on L1210 leukaemia after BCNU chemotherapy.
    Verloes R; Atassi G; Dumont P; Kanarek L
    Br J Cancer; 1981 Feb; 43(2):201-9. PubMed ID: 7470382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of micrococcus, BCG and related polysaccharides on the proliferation of the L1210 leukaemia.
    Verloes R; Atassi G; Dumont P; Kanarek L
    Br J Cancer; 1978 Nov; 38(5):599-605. PubMed ID: 728349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of lactic acid bacteria on a solid fibrosarcoma, sarcoma-180 and Ehrlich ascites carcinoma.
    Kelkar SM; Shenoy MA; Kaklij GS
    Cancer Lett; 1988; 42(1-2):73-7. PubMed ID: 3141041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapeutic effect of a polyantigenic vaccine in animal tumor models.
    Colón JI; Marchand AM; Román Franco AA; Santiago Delpín EA
    Bol Asoc Med P R; 1981 Apr; 73(4):162-7. PubMed ID: 6946783
    [No Abstract]   [Full Text] [Related]  

  • 9. Isolation and characterization of homogenous rabbit antibodies to Micrococcus lysodeikticus with specificity to the peptidoglycan and to the glucose-N-acetylaminomannuronic acid polymer.
    Wikler M
    Z Immunitatsforsch Exp Klin Immunol; 1975 Jul; 149(2-4):193-200. PubMed ID: 52238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour immunoprophylaxis exerted by the antimicrococcus immunity. I. Influence on the proliferation of murine leukaemic L1210 cells.
    Verloes R; Atassi G; Dumont P; Kanarek L
    Eur J Cancer (1965); 1978 Nov; 14(11):1203-12. PubMed ID: 738326
    [No Abstract]   [Full Text] [Related]  

  • 11. [Effect of BCG on the survival of mice following intraperitoneal administration of Ehrlich ascites tumor cells].
    Jakóbisiak M; Kossakowska AE; Zelechowska M; Kamiński M
    Med Dosw Mikrobiol; 1974; 26(3):235-40. PubMed ID: 4409404
    [No Abstract]   [Full Text] [Related]  

  • 12. The prevention of Ehrlich ascites tumor using intraperitoneal colloidal 198Au. Dose vs. size of inoculum.
    Rogoff EE; Romano R; Hahn EW
    Radiology; 1975 Jan; 114(1):225-6. PubMed ID: 1208864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the growth of the Ehrlich ascites tumor in male and female mice.
    Vincent PC; Nicholls A
    Cancer Res; 1967 Jun; 27(6):1058-65. PubMed ID: 6027198
    [No Abstract]   [Full Text] [Related]  

  • 14. [Immunotherapy of Ehrlich ascites tumor in mice].
    Jakóbisiak M
    Pol Arch Med Wewn; 1980 May; 63(5):503-9. PubMed ID: 7413475
    [No Abstract]   [Full Text] [Related]  

  • 15. Passive immunotherapy of mice bearing Ehrlich ascites tumor expressing human, membrane-bound placental alkaline phosphatase.
    Barka T; Henderson S; van der Noen HM
    Tumour Biol; 2000; 21(3):145-52. PubMed ID: 10754465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of bleomycin on the cell cycle of Ehrlich ascites carcinoma.
    Nagatsu M; Richart RM; Lambert A
    Cancer Res; 1972 Sep; 32(9):1966-70. PubMed ID: 4118376
    [No Abstract]   [Full Text] [Related]  

  • 17. Promotion of resistance to Ehrlich ascites carcinoma cells by injection of tumor cells mixed with yeast cell wall.
    Mifuchi I; Hosoi M; Yokokura T
    Gan; 1969 Dec; 60(6):655-6. PubMed ID: 5368343
    [No Abstract]   [Full Text] [Related]  

  • 18. Hematogenous dissemination of tumour cells and metastases formation in Ehrlich ascites tumour.
    Kiseleva NS; Magamadov YC
    Neoplasma; 1972; 19(4):257-75. PubMed ID: 5054530
    [No Abstract]   [Full Text] [Related]  

  • 19. Antitumour immunoprotection by an immunobacterial lectin approach.
    Verloes R; Kanarek L; Atassi G
    Eur J Cancer (1965); 1976 Nov; 12(11):877-88. PubMed ID: 991898
    [No Abstract]   [Full Text] [Related]  

  • 20. [Resistance to colchicine in a glycogen-containing subline of the Ehrlich-Lettré-ascites-tumour].
    Granzow C; Ehe-Galster U
    Z Krebsforsch; 1970; 74(4):329-37. PubMed ID: 4253580
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.